Sales of Mircera Progressing Slowly
Posted on May 16, 2008
Filed Under Biopharmaceuticals, Erythropoietin Stimulating Agents | Leave a Comment
Mircera (methoxy polyethylene glycol-epoetin beta), the first continuous erythropoietin receptor activator for the treatment of symptomatic anemia associated with chronic kidney disease, has now been approved in 54 countries and is currently marketed in 23.
Sales of Mircera are progressing slowly due to the challenging overall market environment but are increasing as Roche wins more contracts and launches the product in additional markets.
In the patent dispute with Amgen, Roche has appealed against a court order that prevents the sale of Mircera in the United States. The appeal is currently pending before the Federal Circuit Court of Appeals in Washington, DC.